Skip to main content
GANX
NASDAQ Life Sciences

Rexaceract Shows 12-Month Motor Stability in Parkinson's, Phase 2 Set for 1Q27

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.74
Mkt Cap
$75.94M
52W Low
$1.53
52W High
$4.34
52W Position info
14% above low
Off High info
60% below high
Rel. Volume
Market data snapshot near publication time

GANX is trading near its 52-week low of $1.53 (14% above the low).

Summary

Gain Therapeutics presented 12-month open-label extension data for rexaceract in Parkinson's disease, showing MDS-UPDRS motor scores remained stable with no clinically meaningful progression in 12 evaluable participants. The company also announced plans to submit a new Phase 2 protocol to the FDA in the coming weeks and initiate the trial in 1Q27. This follows the 8-K filed earlier today and the CFO resignation on September 28, adding clinical momentum amid a going concern warning and limited cash runway. The data supports disease-modifying potential and could attract partnership interest, but the company's financial constraints remain a key risk. Watch for the FDA protocol submission and any partnership announcements in the near term.

At the time of this announcement, GANX was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $1.53 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $1.16 info
Change: +$0.080 (+7%) info
Market Cap: $52.095M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.16 info
Change: -$0.5925 (-34%) info
Market Cap: $52.095M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.16 info
Change: -$0.8426 (-42%) info
Market Cap: $52.095M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.16 info
Change: -$0.900 (-44%) info
Market Cap: $52.095M info
GANX
Jul 16, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.16 info
Change: -$0.520 (-31%) info
Market Cap: $52.095M info